Insmed (INSM) Misses Q3 EPS by 1c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Insmed Reports Third Quarter 2019 Financial Results and Provides Business Update
October 30, 2019 7:30 AM EDTBRIDGEWATER, N.J., Oct. 30, 2019 /PRNewswire/ --Â Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended September 30, 2019 and provided a business update. Â
"We remain very pleased with the continued strong performance of the US launch of ARIKAYCE® (amikacin liposome inhalation suspension). Insmed remains guided by our desire to have a positive impact on patients' lives and is powered by our shared sense of purpose to deliver therapies to small patient populations... More
